PROTHENA CORPORATION PUBLIC LIMITED COMPANY Income (Loss) from Continuing Operations before Income Taxes, Domestic
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$191.82 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-27
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$191.82M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$129.60M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$153.92M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$119.57M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$191.82M 10-K · filed 2026-02-27 |
| 2024-12-31 | -$129.60M 10-K · filed 2026-02-27 |
| 2023-12-31 | -$153.92M 10-K · filed 2026-02-27 |
| 2022-12-31 | -$119.57M 10-K · filed 2025-02-27 |
| 2016-12-31 | -$164.80M 10-K · filed 2017-02-27 |
| 2015-12-31 | -$83.01M 10-K · filed 2017-02-27 |
| 2014-12-31 | -$9.71M 10-K · filed 2017-02-27 |
| 2013-12-31 | -$42.52M 10-K · filed 2016-02-25 |
| 2012-12-31 | -$35.90M 10-K · filed 2015-03-13 |
| 2011-12-31 | -$27.62M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |